Publications en collaboration avec des chercheurs de Universitat Autònoma de Barcelona (11)

2024

  1. CEA-CD3 bispecific antibody cibisatamab with or without atezolizumab in patients with CEA-positive solid tumours: results of two multi-institutional Phase 1 trials

    Nature Communications, Vol. 15, Núm. 1

2021

  1. Atezolizumab in locally advanced or metastatic urothelial cancer: a pooled analysis from the Spanish patients of the IMvigor 210 cohort 2 and 211 studies

    Clinical and Translational Oncology, Vol. 23, Núm. 4, pp. 882-891

  2. CD137 Costimulation Counteracts TGFβ Inhibition of NK-cell Antitumor Function

    Cancer Immunology Research, Vol. 9, Núm. 12, pp. 1476-1490

2020

  1. Final Overall Survival Analysis of the SOGUG Phase 2 MAJA Study: Maintenance Vinflunine Versus Best Supportive Care After First-Line Chemotherapy in Advanced Urothelial Carcinoma

    Clinical Genitourinary Cancer, Vol. 18, Núm. 6, pp. 452-460

2019

  1. Correction to: SEOM clinical guideline for treatment of kidney cancer (2017) (Clinical and Translational Oncology, (2018), 20, 1, (47-56), 10.1007/s12094-017-1765-4)

    Clinical and Translational Oncology

2018

  1. SEOM clinical guideline for treatment of kidney cancer (2017)

    Clinical and Translational Oncology, Vol. 20, Núm. 1, pp. 47-56

2017

  1. HIF pathway and c-Myc as biomarkers for response to sunitinib in metastatic clear-cell renal cell carcinoma

    OncoTargets and Therapy, Vol. 10, pp. 4635-4643

  2. Maintenance therapy with vinflunine plus best supportive care versus best supportive care alone in patients with advanced urothelial carcinoma with a response after first-line chemotherapy (MAJA; SOGUG 2011/02): a multicentre, randomised, controlled, open-label, phase 2 trial

    The Lancet Oncology, Vol. 18, Núm. 5, pp. 672-681

2009

  1. Hacia un programa de Garantía Externa de Calidad para Laboratorios de Inmunología Diagnóstica asociado a la Sociedad Española de Inmunología (GECLID-SEI)

    Inmunologia

2008

  1. Immunotherapy for neurological diseases

    Clinical Immunology

2002

  1. Deregulated expression of the PCPH proto-oncogene in rat mammary tumors induced with 7, 12-dimethylbenz[a]anthracene

    Molecular Carcinogenesis, Vol. 33, Núm. 4, pp. 219-227